USPTO trademark

INTEGRACAR-T

Under examinationUSPTOWord markClass 1Class 5Class 40Class 42

"INTEGRACAR-T" is a word mark owned by CRISPR Therapeutics AG, filed at the USPTO on October 23, 2026. It is under examination and covers classes 1, 5, 40 and 42.

View CRISPR Therapeutics AG portfolioGet this data via the API
Official USPTO record
INTEGRACAR-T trademark as filed
As filed with the USPTO
Status
Under examination
Since October 23, 2026
Filed
October 23, 2026
Registered
Not yet
Expires
Not recorded
Application no.
50177838
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
4 classes
Ownership

Who owns INTEGRACAR-T

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

CRISPR Therapeutics AG

Zug V8, Switzerland

12 trademarks in the portfolioView company

Representative

Tiffany D. Gehrke

Marshall, Gerstein & Borun LLP

Goods and services

What the mark covers

The products and services INTEGRACAR-T is filed for, grouped by Nice class.

  • Delivery vehicles, namely, targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids for in vivo, ex vivo, or in vitro scientific research and medical research; Delivery vehicles, namely, targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids for use in the manufacture of pharmaceuticals for treating cancers, inflammatory disorders, immunoregulatory disorders, autoimmune disorders, metabolic disorders and infectious disorders

  • Medical, biological and pharmaceutical preparations for scientific, research, medical, or pharmaceutical use, namely, preparations for treating cancers, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders; medical, biological and pharmaceutical preparations containing polypeptide or chimeric antigen receptor (CAR) encoding nucleic acids for the prevention and treatment of rare diseases, cancers, inflammatory disorders, immunoregulatory disorders, autoimmune disorders, metabolic disorders, and infectious disorders; RNA-based therapeutics and therapeutic agents, and delivery vehicles, namely, targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids, for in vitro preparation and in vivo or ex vivo delivery to cell sites outside or inside an organism; Medical diagnostic reagents

  • Custom biomanufacturing of pharmaceutical drug substances and drug products

  • Conducting clinical trials for others; Scientific research and development in the field of targeted lipid nanoparticles (tLNPs) carrying chimeric antigen receptor (CAR)-encoding nucleic acids for treating cancers, inflammatory disorders, immunoregulatory disorders, autoimmune disorders, metabolic disorders and infectious disorders; Scientific research and development in the field of RNA-based therapeutics and therapeutic agents; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy.

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Application filing receipt mailed
  2. New application entered
FAQ

About INTEGRACAR-T

Who owns the trademark "INTEGRACAR-T"?

The USPTO trademark "INTEGRACAR-T" (application 50177838) is owned by CRISPR Therapeutics AG.

What is the status of "INTEGRACAR-T"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull INTEGRACAR-T and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_01a16e03-ae78-76d8-b26d-05a69d612921
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_01a16e03-ae78-76d8-b26d-05a69d612921",
  "object": "trademark",
  "mark_text": "INTEGRACAR-T",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "50177838",
  "filing_date": "2026-10-23",
  "nice_classes": [
    1,
    5,
    40,
    42
  ],
  "owners": [
    {
      "name": "CRISPR Therapeutics AG",
      "entity_id": "ent_019f286d-8c9f-713f-87fe-9d4e8b7e3851"
    }
  ]
}